These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35122349)

  • 41. EBV in T-/NK-Cell Tumorigenesis.
    Kimura H
    Adv Exp Med Biol; 2018; 1045():459-475. PubMed ID: 29896680
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders.
    Cai Q; Chen K; Young KH
    Exp Mol Med; 2015 Jan; 47(1):e133. PubMed ID: 25613730
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cutaneous EBV-related lymphoproliferative disorders.
    Gru AA; Jaffe ES
    Semin Diagn Pathol; 2017 Jan; 34(1):60-75. PubMed ID: 27988064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic Active Epstein-Barr Virus Infection: Is It Immunodeficiency, Malignancy, or Both?
    Fujiwara S; Nakamura H
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33143184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic Epstein-Barr Virus-Positive T/NK Lymphoproliferative Diseases With
    Ishimura M; Eguchi K; Shiraishi A; Sonoda M; Azuma Y; Yamamoto H; Imadome KI; Ohga S
    Front Pediatr; 2019; 7():183. PubMed ID: 31231620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epstein-Barr Virus Genome Deletions in Epstein-Barr Virus-Positive T/NK Cell Lymphoproliferative Diseases.
    Wongwiwat W; Fournier B; Bassano I; Bayoumy A; Elgueta Karstegl C; Styles C; Bridges R; Lenoir C; BoutBoul D; Moshous D; Neven B; Kanda T; Morgan RG; White RE; Latour S; Farrell PJ
    J Virol; 2022 Jun; 96(12):e0039422. PubMed ID: 35612313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clonal origin of Epstein-Barr virus (EBV)-infected T/NK-cell subpopulations in EBV-positive T/NK-cell lymphoproliferative disorders of childhood.
    Ohga S; Ishimura M; Yoshimoto G; Miyamoto T; Takada H; Tanaka T; Ohshima K; Ogawa Y; Imadome K; Abe Y; Akashi K; Hara T
    J Clin Virol; 2011 May; 51(1):31-7. PubMed ID: 21377409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Case report: Cellular therapy for hydroa vacciniforme-like lymphoproliferative disorder in pediatric common variable immunodeficiency with chronic active Epstein-Barr virus infection.
    Grześk E; Kołtan S; Dąbrowska A; Urbańczyk A; Małdyk J; Małkowski B; Bogiel T; Dębski R; Czyżewski K; Wysocki M; Styczyński J
    Front Immunol; 2022; 13():915986. PubMed ID: 35990691
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epstein-Barr virus-positive cytotoxic T-cell lymphoma followed by chronic active Epstein-Barr virus infection-associated T/NK-cell lymphoproliferative disorder: a case report.
    Kato S; Miyata T; Takata K; Shimada S; Ito Y; Tomita A; Elsayed AA; Takahashi E; Asano N; Kinoshita T; Kimura H; Nakamura S
    Hum Pathol; 2013 Dec; 44(12):2849-52. PubMed ID: 24012167
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders.
    Iwatsuki K; Satoh M; Yamamoto T; Oono T; Morizane S; Ohtsuka M; Xu ZG; Suzuki D; Tsuji K
    Arch Dermatol; 2006 May; 142(5):587-95. PubMed ID: 16702496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop.
    Climent F; Nicolae A; de Leval L; Dirnhofer S; Leoncini L; Ondrejka SL; Soma L; Wotherspoon A; Zamo A; Quintanilla-Martinez L; Ng SB
    Virchows Arch; 2023 Sep; 483(3):333-348. PubMed ID: 37646869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. When to suspect inborn errors of immunity in Epstein-Barr virus-related lymphoproliferative disorders.
    Sacco KA; Notarangelo LD; Delmonte OM
    Clin Microbiol Infect; 2023 Apr; 29(4):457-462. PubMed ID: 36209991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and genetic characterization of Epstein-Barr virus-associated T/NK-cell lymphoproliferative diseases.
    Luo H; Liu D; Liu W; Jin J; Bi X; Zhang P; Gu J; Zheng M; Xiao M; Liu X; Zhou J; Wang QF
    J Allergy Clin Immunol; 2023 Apr; 151(4):1096-1109. PubMed ID: 36423698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic Active Epstein-Barr Virus Infection of T/NK-Cell Type Mimicking Classic Hodgkin Lymphoma: Clinicopathologic and Genetic Features of 8 Cases Supporting a Variant With "Hodgkin/Reed-Sternberg-like" Cells of NK Phenotype.
    Chen Z; Liu W; Zhang W; Ye Y; Guan P; Gao L; Zhao S
    Am J Surg Pathol; 2019 Dec; 43(12):1611-1621. PubMed ID: 31305266
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An update on Epstein-Barr virus-and human T-lymphotropic virus type-1-induced cutaneous manifestations. CME Part II.
    Gru AA; Plaza JA; Sanches JA; Miyashiro D; Sangueza OP; Puccio FB; Toussaint S; Sangueza JM
    J Am Acad Dermatol; 2023 May; 88(5):983-998. PubMed ID: 36049582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.
    Okamura T; Kishimoto T; Inoue M; Honda M; Yamashita N; Wakiguchi H; Yagita M; Hosoi G; Sako M; Yasui M; Yagi K; Kawa K
    Bone Marrow Transplant; 2003 Jan; 31(2):105-11. PubMed ID: 12621491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics.
    Wang Y; Zhang M; Xue Q; Zhou H; Chen J; Wang H; Zhang Y; Shi W
    Front Immunol; 2023; 14():1172307. PubMed ID: 37138889
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cutaneous lymphoproliferative disorders associated with Epstein-Barr virus infection: a clinical overview.
    Iwatsuki K; Xu Z; Ohtsuka M; Kaneko F
    J Dermatol Sci; 2000 Apr; 22(3):181-95. PubMed ID: 10698155
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A differential diagnosis method for systemic CAEBV and the prospect of EBV-related immune cell markers via flow cytometry.
    Jin J; Mao X; Zhang D
    Ann Med; 2024 Dec; 56(1):2329136. PubMed ID: 38502913
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epstein-Barr virus-associated B-cell lymphoproliferative disorder meeting the definition of CAEBV B cell disease: a case report.
    Ma Y; Bao Y; Zheng M
    BMC Infect Dis; 2023 Jul; 23(1):453. PubMed ID: 37420238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.